A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-06

Study Completion Date

2023-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase1, open-label, sequential dose-escalation and dose-expansion study of KD033 (SAR445710) in adult participants with advanced or metastatic solid tumors. The main purpose of this study is to test KD033 (SAR445710) at different dose levels to see if it is safe and well tolerated when given once every 2 weeks and when given weekly. Additional purposes of the study are to find out whether the study drug has anti-cancer effects and how the study drug is processed by the body.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of ASN004 in Patients With Advanced Solid Tumors

NCT04410224

Solid Tumor

COMPLETED PHASE1

A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.

NCT02579226

Advanced Solid Tumours

COMPLETED PHASE1

Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors

NCT05450562

Neoplasm

TERMINATED PHASE1/PHASE2

The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer

NCT00243347

Carcinoma Non-Small-Cell Lung Carcinoma Head and Neck Neoplasms

COMPLETED PHASE1

SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors

NCT03774979

Solid Tumor

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The foreseen treatment duration is until disease progression, unacceptable toxicity, criterion for withdrawal or for a maximum of 2 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bi-weekly Monotherapy Dose Escalation (Q2W)

KD033 (SAR445710) will be administered in sequential ascending doses as a monotherapy via intravenous (IV) administration every 2 weeks (Q2W).

Group Type EXPERIMENTAL

KD033 (SAR445710)

Intervention Type DRUG

Pharmaceutical form: Solution for infusion Route of administration: intravenous (IV)

Weekly Monotherapy Dose Escalation (Q1W)

KD033 (SAR445710) will be administered in sequential ascending doses as a monotherapy via intravenous (IV) administration once a week (QW) for 6 weeks and then every 2 week-dosing.

Group Type EXPERIMENTAL

KD033 (SAR445710)

Intervention Type DRUG

Pharmaceutical form: Solution for infusion Route of administration: intravenous (IV)

Dose Expansion

KD033 (SAR445710) will be administered at recommended dose/schedule for expansion

Group Type EXPERIMENTAL

KD033 (SAR445710)

Intervention Type DRUG

Pharmaceutical form: Solution for infusion Route of administration: intravenous (IV)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

KD033 (SAR445710)

Pharmaceutical form: Solution for infusion Route of administration: intravenous (IV)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically or cytologically confirmed/documented advanced and/or metastatic solid tumor with at least one tumor lesion of location accessible to biopsy per clinical judgement of treating physician.
* Participants must be willing to provide a tumor biopsy at the following time points: Pre-treatment and at Cycle 4, Day 1. All other study eligibility criteria must be met before any biopsy sample is obtained.
* Measurable disease at baseline per RECIST v1.1 guidelines.
* Life expectancy of at least 3 months.
* Eastern Cooperative Oncology Group Performance Status (ECOG PS) score ≤ 1.
* Adequate organ and bone marrow functions.
* All toxicities related to prior radiotherapy, chemotherapy, or surgical procedure must have recovered to baseline or Grade ≤ 1 based on NCI-CTCAE v5.0 except alopecia (any grade), Grade 2 peripheral neuropathy and adverse events that are clinically non-significant or stable on supportive care.
* All participants, male and female, who are not surgically sterilized or postmenopausal must agree to use 'highly effective methods of contraception' during the study and for at least 60 days after the last dose of KD033 (SAR445710).
* Women of childbearing potential must have a negative pregnancy test within 7 days prior to KD033 (SAR445710) treatment.
* Ability to understand the purpose of the study, provide signed and dated informed consent from the participant/legal representative prior to performing any protocol-related procedures and able to comply with the study procedures and any locally required authorization.

Exclusion Criteria

* Use of immunotherapy, biological therapy, cytokine therapy \< 21 days prior to the first dose of study drug.
* Use of immunomodulating agents \< 21 days prior to the first dose of study drug.
* Use of chemotherapy and approved tyrosine kinase inhibitor (TKI) therapy \< 14 days prior to the first dose of study drug.
* Anti PD-L1 or anti PD-1 therapy \< 6 weeks prior to the first dose of study drug.
* Radiotherapy within 14 days before the start of trial treatment (prior diagnostic biopsy is permitted), with the exception of palliative radiation as described: patients assigned to radiotherapy require at least 1 additional lesion that can be safely irradiated while sparing the index lesion(s), and for which radiation at the limited, palliative doses contemplated would be considered medically appropriate; The lesion should be causing some signs or symptoms (e.g., tumor-related pain), for which radiation is indicated per the physician's standard clinical practice.
* Use of any investigational drug or have major surgery within 28 days before the start of trial treatment
* Ongoing or recent (within 2 years) evidence of significant autoimmune disease that required systemic immunosuppressive treatments.
* Systemic therapy with immunosuppressive agents including corticosteroids within 14 days before the start of trial treatment with the exception of corticosteroid replacement therapy for adrenal insufficiency
* Rapidly progressive disease which, in the opinion of Investigator, may predispose to inability to tolerate treatment or trial procedure.
* History or clinical evidence of central nervous system primary tumors or metastases including leptomeningeal metastases unless they have been previously treated, demonstrated no progression at least 1 months, are asymptomatic and have had no requirement for steroids or enzyme inducing anticonvulsants in the last 14 days before Screening - Participants with suspected brain metastases at Screening should undergo a CT/MRI of the brain prior to study entry.
* Receipt of any organ transplantation including hematopoietic cell transplantation.
* Has a paraneoplastic syndrome of autoimmune nature.
* History of interstitial lung disease or severe obstructive pulmonary disease.
* Clinically significant cardiovascular/cerebrovascular disease.
* QTc(F) interval \> 450 ms for men or \> 470 ms for women)
* Left ventricular ejection fraction (LVEF) \< 50% as measured by an echocardiogram (ECHO).
* Active infection requiring therapy.
* Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding.
* Pregnant or breast-feeding women
* Known severe hypersensitivity reactions to monoclonal antibodies, any history of or recent (within 6 months) of anaphylaxis
* Vaccine administration within 4 weeks of investigational drug administration.
* Vaccination with live vaccines while on trial is prohibited. Administration of inactivated vaccines like inactivated influenza vaccines is allowed. COVID-19 vaccines are approved to be administered prior to KD033 (SAR445710) administration and during the treatment phase, however, it is preferred to not vaccinate during the 28-day DLT period.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No